Madan Katragadda,
Senior Principal Scientist,
Pfizer
Dr. Madan Katragadda is a Senior Principal Scientist in the department of Global Biotherapeutic Technologies at Pfizer Inc. He is leading a team of scientists actively involved in antibody generation and engineering for biotherapeutic development including Antibody drug conjugates and bispecifics. His research interests also include engineering alternative antibody formats for oncology applications
Generation of an Optimal Antibody-Drug Conjugate for Oncology Therapy: Evolving Guiding Principles
Tuesday, 3 March 2015 at 09:30
Add to Calendar ▼2015-03-03 09:30:002015-03-03 10:30:00Europe/LondonGeneration of an Optimal Antibody-Drug Conjugate for Oncology Therapy: Evolving Guiding PrinciplesCurrent Trends in Antibody Drug Conjugates in Bangalore, IndiaBangalore, IndiaSELECTBIOenquiries@selectbiosciences.com
This presentation will discuss the principles
involved in generation of ADCs for Oncology Therapy. Further, it will focus on engineering and optimization of tumor targeting antibody vehicle,
conjugation strategy, and chemistry of linker-payload. Factors that guide the optimization
of antibody vehicle to suit the linker-payload and conjugation chemistry will
also be discussed.
Add to Calendar ▼2015-03-02 00:00:002015-03-03 00:00:00Europe/LondonCurrent Trends in Antibody Drug ConjugatesCurrent Trends in Antibody Drug Conjugates in Bangalore, IndiaBangalore, IndiaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2015-03-03 09:30:002015-03-03 10:30:00Europe/LondonGeneration of an Optimal Antibody-Drug Conjugate for Oncology Therapy: Evolving Guiding PrinciplesCurrent Trends in Antibody Drug Conjugates in Bangalore, IndiaBangalore, IndiaSELECTBIOenquiries@selectbiosciences.com
